Salarius Pharmaceuticals Inc. has announced a management change with the appointment of Mark J. Rosenblum as the acting Chief Executive Officer, effective August 17, 2025. Rosenblum, who will continue his role as Executive Vice President and Chief Financial Officer, succeeds David J. Arthur, who resigned as CEO but remains on the Board. The change is part of Salarius's ongoing strategic developments, including its merger with Decoy Therapeutics Inc.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001615219-25-000107), on August 18, 2025, and is solely responsible for the information contained therein.